2025
A positron emission tomography tracer for the imaging of oxidative stress in the central nervous system
Wilde J, Sun Y, Simpson S, Hill E, Fu Z, Bian E, Kinkaid M, Villanueva P, Weybright A, Terrell W, Qureshi Z, Perera S, Sheppard H, Stone J, Kundu B, Kuan C, Neumann K. A positron emission tomography tracer for the imaging of oxidative stress in the central nervous system. Nature Biomedical Engineering 2025, 1-14. PMID: 40044816, DOI: 10.1038/s41551-025-01362-3.Peer-Reviewed Original ResearchCentral nervous systemPositron emission tomographyInjection of sodium nitroprussideOxidative stressNervous systemClinical trials of antioxidantsMiddle cerebral arteryBlood-brain barrierTrials of antioxidantsPositron emission tomography tracersIntrastriatal injectionParametric mappingSodium nitroprussideCerebral arteryLongitudinally in vivoIn vivo quantificationQuantification of oxidative stressEmission tomographyPET imagingAntioxidant edaravoneDynamic PET imagesHuman plasmaDeep learning to quantify the pace of brain aging in relation to neurocognitive changes
Yin C, Imms P, Chowdhury N, Chaudhari N, Ping H, Wang H, Bogdan P, Irimia A, Weiner M, Aisen P, Petersen R, Jack C, Jagust W, Landau S, Rivera-Mindt M, Okonkwo O, Shaw L, Lee E, Toga A, Beckett L, Harvey D, Green R, Saykin A, Nho K, Perrin R, Tosun D, Sachdev P, Green R, Drake E, Montine T, Conti C, Weiner M, Nosheny R, Truran Sacrey D, Fockler J, Miller M, Conti C, Kwang W, Jin C, Diaz A, Ashford M, Flenniken D, Kormos A, Petersen R, Aisen P, Rafii M, Raman R, Jimenez G, Donohue M, Salazar J, Fidell A, Boatwright V, Robison J, Zimmerman C, Cabrera Y, Walter S, Clanton T, Shaffer E, Webb C, Hergesheimer L, Smith S, Ogwang S, Adegoke O, Mahboubi P, Pizzola J, Jenkins C, Beckett L, Harvey D, Donohue M, Saito N, Diaz A, Hussen K, Okonkwo O, Rivera-Mindt M, Amaza H, Thao M, Parkins S, Ayo O, Glittenberg M, Hoang I, Germano K, Strong J, Weisensel T, Magana F, Thomas L, Guzman V, Ajayi A, Di Benedetto J, Talavera S, Jack C, Felmlee J, Fox N, Thompson P, DeCarli C, Forghanian-Arani A, Borowski B, Reyes C, Hedberg C, Ward C, Schwarz C, Reyes D, Gunter J, Moore-Weiss J, Kantarci K, Matoush L, Senjem M, Vemuri P, Reid R, Malone I, Thomopoulos S, Nir T, Jahanshad N, Knaack A, Fletcher E, Harvey D, Tosun-Turgut D, Rossi Chen S, Choe M, Crawford K, Yushkevich P, Das S, Jagust W, Landau S, Koeppe R, Rabinovici G, Villemagne V, LoPresti B, Perrin R, Morris J, Franklin E, Bernhardt H, Cairns N, Taylor-Reinwald L, Shaw L, Lee E, Lee V, Korecka M, Brylska M, Wan Y, Trojanowki J, Toga A, Crawford K, Neu S, Saykin A, Nho K, Foroud T, Jo T, Risacher S, Craft H, Apostolova L, Nudelman K, Faber K, Potter Z, Lacy K, Kaddurah-Daouk R, Shen L, Karlawish J, Erickson C, Grill J, Largent E, Harkins K, Weiner M, Thal L, Kachaturian Z, Frank R, Snyder P, Buckholtz N, Hsiao J, Ryan L, Molchan S, Khachaturian Z, Carrillo M, Potter W, Barnes L, Bernard M, González H, Ho C, Hsiao J, Jackson J, Masliah E, Masterman D, Okonkwo O, Perrin R, Ryan L, Silverberg N, Silbert L, Kaye J, White S, Pierce A, Thomas A, Clay T, Schwartz D, Devereux G, Taylor J, Ryan J, Nguyen M, DeCapo M, Shang Y, Schneider L, Munoz C, Ferman D, Conant C, Martin K, Oleary K, Pawluczyk S, Trejo E, Dagerman K, Teodoro L, Becerra M, Fairooz M, Garrison S, Boudreau J, Avila Y, Brewer J, Jacobson A, Gama A, Kim C, Little E, Frascino J, Ferng N, Trujillo S, Heidebrink J, Koeppe R, MacDonald S, Malyarenko D, Ziolkowski J, O’Connor J, Robert N, Lowe S, Rogers V, Petersen R, Hackenmiller B, Boeve B, Albers C, Kreuger C, Jones D, Knopman D, Botha H, Magnuson J, Graff-Radford J, Crawley K, Schumacher M, McKinzie S, Smith S, Helland T, Lowe V, Ramanan V, Pavlik V, Faircloth J, Bishop J, Nath J, Chaudhary M, Kataki M, Yu M, Pacini N, Barker R, Brooks R, Aggarwal R, Honig L, Stern Y, Mintz A, Cordona J, Hernandez M, Long J, Arnold A, Groves A, Middleton A, Vogler B, McCurry C, Mayo C, Raji C, Amtashar F, Klemp H, Elmore H, Ruszkiewicz J, Kusuran J, Stewart J, Horenkamp J, Greeson J, Wever K, Vo K, Larkin K, Rao L, Schoolcraft L, Gallagher L, Paczynski M, McMillan M, Holt M, Gagliano N, Henson R, LaBarge R, Swarm R, Munie S, Cepeda S, Winterton S, Hegedus S, Wilson T, Harte T, Bonacorsi Z, Geldmacher D, Watkins A, Barger B, Smelser B, Bates C, Stover C, McKinley E, Ikner G, Hendrix H, Cooper H, Mahaffey J, Booth Robbins L, Brown Ashley L, Natelson-Love M, Carter P, Solomon V, Grossman H, Groome A, Ardolino A, Kaplan A, Sheppard F, Burgos-Rivera G, Garcia-Camilo G, Lim J, Neugroschl J, Jackson K, Evans K, Soleimani L, Sano M, Ghesani N, Binder S, Apuango X, Sood A, Troutman A, Blanchard K, Richards A, Nelson G, Hendrickson K, Yurko E, Plenge J, Rufo V, Shah R, Duara R, Lynch B, Chirinos C, Dittrich C, Campbell D, Mejia D, Perez G, Colvee H, Gonzalez J, Gondrez J, Knaack J, Acevedo M, Cereijo M, Greig-Custo M, Villar M, Wishnia M, Detling S, Barker W, Albert M, Moghekar A, Rodzon B, Demsky C, Pontone G, Pekar J, Farrington L, Pomper M, Johnson N, Alo T, Sadowski M, Ulysse A, Masurkar A, Marti B, Mossa D, Geesey E, Petrocca E, Schulze E, Wong J, Boonsiri J, Kenowsky S, Martinez T, Briglall V, Doraiswamy P, Nwosu A, Adhikari A, Hellegers C, Petrella J, James O, Wong T, Hawk T, Vaishnavi S, McCoubrey H, Nasrallah I, Rovere R, Maneval J, Robinson E, Rivera F, Uffelman J, Combs M, O’Donnell P, Manning S, King R, Nieto A, Glueck A, Mandal A, Swain A, Gamble B, Meacham B, Forenback D, Ross D, Cheatham E, Hartman E, Cornell G, Harp J, Ashe L, Goins L, Watts L, Yazell M, Mandal P, Buckler R, Vincent S, Rudd T, Lopez O, Malia A, Chiado C, Zik C, Ruszkiewicz J, Savage K, Fenice L, Oakley M, Tacey P, Berman S, Bowser S, Hegedus S, Saganis X, Porsteinsson A, Mathewson A, Widman A, Holvey B, Clark E, Morales E, Young I, Ruszkiewicz J, Hopkins K, Martin K, Kowalski N, Hunt R, Calzavara R, Kurvach R, D’Ambrosio S, Thai G, Vides B, Lieb B, McAdams-Ortiz C, Toso C, Mares I, Moorlach K, Liu L, Corona M, Nguyen M, Tallakson M, McDonnell M, Rangel M, Basheer N, Place P, Romero R, Tam S, Nguyen T, Thomas A, Frolov A, Khera A, Browning A, Kelley B, Dawson C, Mathews D, Most E, Phillips E, Nguyen L, Nunez M, Miller M, Jones M, Martinez N, Logan R, McColl R, Pham S, Fox T, Moore T, Levey A, Brown A, Kippels A, Ellison A, Lyons C, Hales C, Parry C, Williams C, McCorkle E, Harris G, Rose H, Jooma I, Al-Amin J, Lah J, Webster J, Swiniarski J, Chapman L, Donnelly L, Mariotti L, Locke M, Vaughn P, Penn R, Carpentier S, Yeboah S, Basadre S, Malakauskas S, Lyron S, Villinger T, Burney T, Burns J, Abusalim A, Dahlgren A, Montero A, Arthur A, Dooly H, Kreszyn K, Berner K, Gillen L, Scanlan M, Madison M, Mathis N, Switzer P, Townley R, Fikru S, Sullivan S, Wright E, Beigi M, Daley A, Ko A, Luong B, Nyborg G, Morales J, Durbin K, Garcia L, Parand L, Macias L, Monserratt L, Farchi M, Wu P, Hernandez R, Rodriguez T, Graff-Radford N, Marolt A, Thomas A, Aloszka D, Moncayo E, Westerhold E, Day G, Chrestensen K, Imhansiemhonehi M, McKinzie S, Stephens S, Grant S, Brosch J, Perkins A, Saunders A, Kovac D, Polson H, Mwaura I, Mejia K, Britt K, King K, Nichols K, Lawrence K, Rankin L, Farlow M, Wiesenauer P, Bryant R, Herring S, Lynch S, Wilson S, Day T, Korst W, van Dyck C, Mecca A, Miller A, Brennan A, Khan A, Ruan A, Gunnoud C, Mendonca C, Raynes-Goldfinger D, Salardini E, Hidalgo E, Cooper E, Singh E, Murphy E, May J, Stanhope J, Lam J, Waszak J, Nelsen K, Sacaza K, Hasbani M, Donahue M, Chen M, Barcelos N, Eigenberger P, Bonomi R, O’Dell R, Jefferson S, Khasnavis S, Smilowitz S, DeStefano S, Good S, Camarro T, Clayton V, Cavrel Y, Lu Y, Chertkow H, Bergman H, Hosein C, Black S, Kapadia A, Bhan A, Lam B, Scott C, Gabriel G, Bray J, Zotovic L, Gutierrez M, Masellis M, Farshadi M, Gui M, Mitchell M, Taylor R, Endre R, Taghi-Zada Z, Hsiung R, English C, Kim E, Yau E, Tong H, Barlow L, Jennings L, Assaly M, Nunes P, Marian T, Kertesz A, Rogers J, Trost D, Wint D, Bernick C, Munic D, Grant I, Korkoyah A, Raja A, Lapins A, Ryan C, Pejic J, Basham K, Lukose L, Haddad L, Quinlan L, Houghtaling N, Sadowsky C, Martinez W, Villena T, Reynolds B, Forero A, Ward C, Brennan E, Figueroa E, Esposito G, Mallory J, Johnson K, Turner K, Seidenberg K, McCann K, Bassett M, Chadwick M, Turner R, Bean R, Sharma S, Marshall G, Haviari A, Pietras A, Wallace B, Munro C, Rivera-Delpin G, Hustead H, Levesque I, Ramirez J, Nolan K, Glennon K, Palou M, Erkkinen M, DaSilva N, Friedman P, Silver R, Salazar R, Polleys R, McGinnis S, Gale S, Hall T, Luu T, Chao S, Lin E, Coleman J, Epperson K, Vasanawala M, Atri A, Rangel A, Evans B, Monarrez C, Cline C, Liebsack C, Bandy D, Goldfarb D, Intorcia D, Olgin J, Clark K, King K, York K, Reade M, Callan M, Glass M, Johnson M, Gutierrez M, Goddard M, Trncic N, Choudhury P, Reyes P, Lowery S, Hall S, Olgin S, de Santiago S, Alosco M, Ton A, Jimenez A, Ellison A, Tran A, Anderson B, Carter D, Veronelli D, Lenio S, Steinberg E, Mez J, Weller J, Johns J, Mez J, Harkins J, Puleio A, Hoti I, Mwicigi J, Puleio A, Alosco M, Schultz O, Lauture M, Steinberg E, Denis R, Killiany R, Singh S, Lenio S, Qiu W, Devis Y, Obisesan T, Stone A, Ordor D, Udodong I, Okonkwo I, Khan J, Turner J, Hughes K, Kadiri O, Duffy C, Moss A, Stapleton K, Toth M, Sanders M, Ayres M, Hamski M, Fatica P, Ogrocki P, Ash S, Pot S, Chen D, Soto A, Tanase C, Bissig D, Vanya H, Russell H, Patel H, Zhang H, Wallace K, Ayers K, Gallegos M, Forloines M, Sinn M, Kahulugan Q, Isip R, Calderon S, Hamm T, Borrie M, Lee T, Bartha R, Johnson S, Asthana S, Carlsson C, Perrin A, Tariot P, Fleisher A, Reeder S, Capote H, Emborsky A, Mattle A, Ajtai B, Wagner B, Myers B, Slazyk D, Fragale D, Fransen E, Macnamara H, Falletta J, Hirtreiter J, Mechtler L, King M, Asbach M, Rainka M, Zawislak R, Wisniewski S, O’Malley S, Jimenez-Knight T, Peehler T, Aladeen T, Bates V, Wenner V, Elmalik W, Scharre D, Ramamurthy A, Bouchachi S, Kataki M, Tarawneh R, Kelley B, Celmins D, Leader A, Figueroa C, Bauerle H, Patterson K, Reposa M, Presto S, Ahmed T, Stewart W, Pearlson G, Blank K, Anderson K, Santulli R, Schwartz E, Williamson J, Jessup A, Williams A, Duncan C, O’Connell A, Gagnon K, Zamora E, Bateman J, Crawford F, Thompson D, Walker E, Rowell J, White M, Ledford P, Bohlman S, Henkle S, Bottoms J, Moretz L, Hoover B, Shannon M, Rogers S, Baker W, Harrison W, Wu C, DeMarco A, Stipanovich A, Arcuri D, Clark J, Davis J, Doyon K, Amoyaw M, Acosta M, Bailey R, Warren S, Fogerty T, Sanborn V, Riddle M, Salloway S, Malloy P, Correia S, Windon C, Blackburn M, Rosen H, Miller B, Smith A, Mba I, Echevarria J, Janavs J, Roglaski E, Yong M, Devine R, Okhravi H, Rivera E, Kalowsky T, Smith C, Rosario C, Masdeu J, Le R, Gurung M, Sabbagh M, Garcia A, Ellis Slaughter M, Elayan N, Acothley S, Pomara N, Hernando R, Pomara V, Reichert C, Brawman-Mintzer O, Acree A, Williams A, Long C, Long R, Newhouse P, Hill S, Boegel A, Seshadri S, Saklad A, Jones F, Hu W, Sotelo V, Gonazalez Rojas Y, Mintzer J, Flynn Longmire C, Spicer K. Deep learning to quantify the pace of brain aging in relation to neurocognitive changes. Proceedings Of The National Academy Of Sciences Of The United States Of America 2025, 122: e2413442122. PMID: 39993207, PMCID: PMC11912385, DOI: 10.1073/pnas.2413442122.Peer-Reviewed Original ResearchConceptsCN adultsBrain agingNeuroanatomical agingLongitudinal modelAdverse cognitive changesChronological ageAlzheimer's diseaseNeurocognitive agingCognitive changesNeurocognitive changesCognitive functionNeurocognitive statusAssociated with changesAge trendsLongitudinal MRIAdultsBrainQuantify DNA methylationAD risk assessmentBlood-brain barrierEndothelial SHANK3 regulates tight junctions in the neonatal mouse blood-brain barrier through β-Catenin signaling
Kim Y, Kim M, Kim S, Lee R, Ujihara Y, Marquez-Wilkins E, Jiang Y, Yang E, Kim H, Lee C, Park C, Kim I. Endothelial SHANK3 regulates tight junctions in the neonatal mouse blood-brain barrier through β-Catenin signaling. Nature Communications 2025, 16: 1407. PMID: 39915488, PMCID: PMC11802743, DOI: 10.1038/s41467-025-56720-1.Peer-Reviewed Original ResearchConceptsBlood-brain barrierNeuronal excitabilityB-cateninBarrier functionMouse blood-brain barrierReduced neuronal excitabilityMale mutant miceBlood-brain barrier permeabilityBrain endothelial cellsAutism spectrum disorderNeonatal micePotential therapeutic targetASD risk genesMutant miceTight junctionsImpaired sociabilityPathogenic mechanismsBrain parenchymaEndothelial cellsTherapeutic targetASD pathogenesisSHANK3Adult ageDisabling conditionMiceDynamic Contrast-enhanced MRI Processing Comparison for Distinguishing True Progression From Pseudoprogression in High-grade Glioma.
Amer A, Ansari S, Krayyem A, Kundu S, Khose S, Pokhylevych H, Calle S, Patel C, Yang Z, Liu H, Johnson J. Dynamic Contrast-enhanced MRI Processing Comparison for Distinguishing True Progression From Pseudoprogression in High-grade Glioma. Journal Of Computer Assisted Tomography 2025 PMID: 39876523, DOI: 10.1097/rct.0000000000001716.Peer-Reviewed Original ResearchHigh-grade gliomasBlood-brain barrierDCE-MRIPeak contrast enhancementQuantify BBB permeabilityTreatment-related changesFollow-up subjectsKtrans mapsTrue progressionTumor progressionClinical dataConventional MRIPseudoprogressionBBB permeabilityCombined pathologyKtransContrast enhancementT1 enhancementStandard processing methodologyStatistically significant resultsClinical data setsPathologyPatientsGliomaSSS techniqueCurrent Advances in PARP1‐Targeted Theranostics
Tong J, Chen B, Volpi T, Li Y, Ellison P, Cai Z. Current Advances in PARP1‐Targeted Theranostics. Journal Of Labelled Compounds And Radiopharmaceuticals 2025, 68: e4135. PMID: 39995212, DOI: 10.1002/jlcr.4135.Peer-Reviewed Original ResearchConceptsPoly (ADP-ribose) polymerase 1Blood-brain barrierCentral nervous systemBlood-tumor barrierPotential clinical useBRCA mutationsHomologous recombination repair pathwayPARP inhibitorsPharmacodynamic evaluationPatient stratificationPersonalized oncologyPharmacological characteristicsClinical useBrain tumorsBrain barrierDiagnostic imagingPET imagingCancerNervous systemTherapeutic interventionsBrain cancerPathophysiological conditionsTreatment assessmentPARPiNeurological disorders
2024
Mesenchymal Stem Cells and Their Extracellular Vesicles: Therapeutic Mechanisms for Blood–Spinal Cord Barrier Repair Following Spinal Cord Injury
Nakazaki M, Yokoyama T, Lankford K, Hirota R, Kocsis J, Honmou O. Mesenchymal Stem Cells and Their Extracellular Vesicles: Therapeutic Mechanisms for Blood–Spinal Cord Barrier Repair Following Spinal Cord Injury. International Journal Of Molecular Sciences 2024, 25: 13460. PMID: 39769223, PMCID: PMC11677717, DOI: 10.3390/ijms252413460.Peer-Reviewed Original ResearchConceptsBlood-spinal cord barrierBSCB repairMesenchymal stromal/stem cellsSpinal cord injuryMSC-EVsMesenchymal stromal/stem cell therapyBlood-spinal cord barrier integritySpinal cord homeostasisBlood-spinal cord barrier permeabilityCord injuryImpaired axonal regenerationTreating spinal cord injuryCell-free alternativeExtracellular vesiclesTight junction proteinsSpinal neural tissueBlood-brain barrierImprove patient outcomesAnti-inflammatory propertiesImmune cellsPreclinical studiesJunction proteinsSecreted extracellular vesiclesClinical trialsReduce inflammationMultimodality Molecular Imaging of Brain Tumor Using Simultaneous [18F]FET-PET/MRSI
Ma C, Han P, Marin T, Zhuo Y, Shih H, Fakhri G. Multimodality Molecular Imaging of Brain Tumor Using Simultaneous [18F]FET-PET/MRSI. 2024, 00: 1-2. DOI: 10.1109/nss/mic/rtsd57108.2024.10656528.Peer-Reviewed Original ResearchList-mode dataMR spectroscopic imagingSpatial resolutionAccurate brain tumor delineationMR physicsIsotropic resolutionBrain tumor delineationImprove treatment planningSpectroscopic imagingTumor delineationSignal-to-noise ratioIntact blood-brain barrierImaging speedAmino acid radiotracerImaging timeMR signalHigher proliferation activityStructural MRTreatment planningBlood-brain barrierMR spectroscopic imaging dataMolecular imaging of brain tumorsTumor involvementTumor infiltrationTumor marginsAPOE 4‐related blood–brain barrier breakdown is associated with microstructural abnormalities
Reas E, Solders S, Tsiknia A, Triebswetter C, Shen Q, Rivera C, Andrews M, Alderson‐Myers A, Brewer J. APOE 4‐related blood–brain barrier breakdown is associated with microstructural abnormalities. Alzheimer's & Dementia 2024, 20: 8615-8624. PMID: 39411970, PMCID: PMC11667544, DOI: 10.1002/alz.14302.Peer-Reviewed Original ResearchAPOE4 carriersAlzheimer's diseaseAmyloid-negative individualsAmyloid-betaAmyloid-positive individualsApoE4AD cascadeAmyloidBlood-brain barrierAPOE 4Magnetic resonance imagingBrain microstructureAbsence of cognitive declinePreclinical ADLinear regression assessed associationsAmyloid positivityNeurodegenerative changesCortical gray matterCognitive declineMicrostructural abnormalitiesAssociated with microstructural abnormalitiesCognitive statusApoNeurodegenerationOlder adultsNanotechnology approaches to drug delivery for the treatment of ischemic stroke
Peng B, Mohammed F, Tang X, Liu J, Sheth K, Zhou J. Nanotechnology approaches to drug delivery for the treatment of ischemic stroke. Bioactive Materials 2024, 43: 145-161. PMID: 39386225, PMCID: PMC11462157, DOI: 10.1016/j.bioactmat.2024.09.016.Peer-Reviewed Original ResearchBlood-brain barrierClinical translationClinical trialsFDA-approved pharmacotherapiesReview therapeutic agentsIschemic strokeTherapeutic agentsEffective treatment optionDrug deliveryTreatment of ischemic strokePotential clinical translationGlobal public health concernImprove delivery efficiencyTreatment optionsTreatment strategiesIschemic brainPublic health concernStroke pharmacotherapyEngineered nanoparticlesStroke treatment strategiesDelivery efficiencyNanotechnological approachesDrugPharmacotherapyStrokemTORC1 Signaling in Brain Endothelial Progenitors Contributes to CCM Pathogenesis
Min W, Qin L, Zhang H, López-Giráldez F, Jiang N, Kim Y, Mohan V, Su M, Murray K, Grutzendler J, Zhou J. mTORC1 Signaling in Brain Endothelial Progenitors Contributes to CCM Pathogenesis. Circulation Research 2024, 135: e94-e113. PMID: 38957991, PMCID: PMC11293987, DOI: 10.1161/circresaha.123.324015.Peer-Reviewed Original ResearchCerebral vascular malformationsEndothelial progenitor cellsBlood-brain barrier integritySingle-cell RNA sequencing analysisDisruption of blood-brain barrier integrityBarrier integrityResident endothelial progenitor cellsRNA sequencing analysisTissue immunofluorescence analysisEndothelial cellsEPC clustersStem cell markersFocal neurological deficitsBrain's neurovascular unitMTOR signalingHuman CCM lesionsMTORC1 signalingBlood-brain barrierCapillary endothelial cellsCCM pathogenesisVascular malformationsLesion signaturesNeurological deficitsCell markersClonal expansionTranscobalamin receptor antibodies in autoimmune vitamin B12 central deficiency
Pluvinage J, Ngo T, Fouassier C, McDonagh M, Holmes B, Bartley C, Kondapavulur S, Hurabielle C, Bodansky A, Pai V, Hinman S, Aslanpour A, Alvarenga B, Zorn K, Zamecnik C, McCann A, Asencor A, Huynh T, Browne W, Tubati A, Haney M, Douglas V, Louine M, Cree B, Hauser S, Seeley W, Baranzini S, Wells J, Spudich S, Farhadian S, Ramachandran P, Gillum L, Hales C, Zikherman J, Anderson M, Yazdany J, Smith B, Nath A, Suh G, Flanagan E, Green A, Green R, Gelfand J, DeRisi J, Pleasure S, Wilson M. Transcobalamin receptor antibodies in autoimmune vitamin B12 central deficiency. Science Translational Medicine 2024, 16: eadl3758. PMID: 38924428, PMCID: PMC11520464, DOI: 10.1126/scitranslmed.adl3758.Peer-Reviewed Original ResearchConceptsBlood-brain barrierCerebrospinal fluidNeurological deficitsAutoimmune neurological conditionsCohort of patientsCellular uptake of cobalaminVitamin B12B12 transportCerebrospinal fluid samplesMeasurement of vitamin B12Low-density lipoprotein receptorProgrammable phage displayImmunosuppressive treatmentIn vitro modelNeuropsychiatric lupusImmunomodulatory treatmentReceptor antibodiesClinical improvementUptake of cobalaminB12 deficiencyUnknown etiologyHematopoietic cellsTranscobalamin receptorCentral deficiencyB12 supplementationCNS cell-derived exosome signatures as blood-based biomarkers of neurodegenerative diseases
Park C, Weerakkody J, Schneider R, Miao S, Pitt D. CNS cell-derived exosome signatures as blood-based biomarkers of neurodegenerative diseases. Frontiers In Neuroscience 2024, 18: 1426700. PMID: 38966760, PMCID: PMC11222337, DOI: 10.3389/fnins.2024.1426700.Peer-Reviewed Original ResearchNeurodegenerative diseasesSubtype of extracellular vesiclesDisease-related processesDisease-associated changesCentral nervous systemBlood-based proteinsBiomarkers of neurodegenerative diseasesBlood-brain barrierCell typesExosome populationMolecular cargoExtracellular vesiclesCell of originRNA biomarkersExosome isolationTranslation to clinical useCell-derived exosomesLack of standardized methodologyMolecular contentExosomesBlood-based biomarkersPeripheral bloodCellsExosome signatureMolecular biomarkersBifunctional Molecules That Induce Both Targeted Degradation and Transcytosis of Extracellular Proteins in Brain Cells
Howell R, Wang S, Khambete M, McDonald D, Spiegel D. Bifunctional Molecules That Induce Both Targeted Degradation and Transcytosis of Extracellular Proteins in Brain Cells. Journal Of The American Chemical Society 2024, 146: 16404-16411. PMID: 38855935, DOI: 10.1021/jacs.3c13320.Peer-Reviewed Original ResearchLow-density lipoprotein receptor-related protein 1Targeted protein degradationTarget proteinsClathrin-mediated mechanismLipoprotein receptor-related protein 1Chloroalkane ligandTranscytosis of proteinsExtracellular proteinsPeptide motifsLysosomal localizationTargeted degradationHaloTag proteinCovalent taggingProtein degradationLysosomal proteolysisBlood-brain barrierProteinDegradable proteinCentral nervous systemProtein 1Bifunctional small moleculesEffective therapeutic strategyPrimary receptorTranscytosisStreptavidinAutocatalytic, Brain Tumor‐Targeting Delivery of Bardoxolone Methyl Self‐Assembled Nanoparticles for Glioblastoma Treatment
Ye Z, Sheu W, Qu H, Peng B, Liu J, Zhang L, Yuan F, Wei Y, Zhou J, Chen Q, Xiao X, Zhang S. Autocatalytic, Brain Tumor‐Targeting Delivery of Bardoxolone Methyl Self‐Assembled Nanoparticles for Glioblastoma Treatment. Small Science 2024, 4 DOI: 10.1002/smsc.202400081.Peer-Reviewed Original ResearchBlood-brain barrierBardoxolone methylGlioblastoma multiformeBrain tumorsSurvival of miceSelf-assembled nanoparticlesInhibited GBM tumor growthEnhance drug penetrationGlioblastoma multiforme treatmentKill GBM cellsLack of effective drugsTumor growthDrug penetrationIntravenous administrationP28 peptideEffective drugsGlioblastoma treatmentTumorClinical applicationGBM cellsPeptide-conjugatesTreatmentBrainBardoxoloneGlioblastomaExploiting Metabolic Defects in Glioma with Nanoparticle-Encapsulated NAMPT Inhibitors
Murray M, Noronha K, Wang Y, Friedman A, Paradkar S, Suh H, Sundaram R, Brenner C, Saltzman W, Bindra R. Exploiting Metabolic Defects in Glioma with Nanoparticle-Encapsulated NAMPT Inhibitors. Molecular Cancer Therapeutics 2024, 23: 1176-1187. PMID: 38691846, PMCID: PMC11292319, DOI: 10.1158/1535-7163.mct-24-0012.Peer-Reviewed Original ResearchConvection-enhanced deliveryCentral nervous systemTreatment of primary central nervous systemPrimary central nervous systemSustained drug release in vitroTumor growth delayAssociated with lower survival ratesBone marrow suppressionComplex mutational profilesNAMPT inhibitorsRelease in vitroIntracranial GBM xenograftsBlood-brain barrierDrug release in vitroRetinal toxicityMarrow suppressionNAMPTiGrowth delayTherapeutic vulnerabilitiesExtended survivalLow survival rateGBM xenograftsMutation profilesPromoter methylationAnticancer activity in vitroT cell-mediated skin-brain axis: Bridging the gap between psoriasis and psychiatric comorbidities
Yang J, Zhang S, Wu Q, Chen P, Dai Y, Long J, Wu Y, Lin Y. T cell-mediated skin-brain axis: Bridging the gap between psoriasis and psychiatric comorbidities. Journal Of Autoimmunity 2024, 144: 103176. PMID: 38364575, DOI: 10.1016/j.jaut.2024.103176.Peer-Reviewed Original ResearchPsychiatric comorbiditiesMental disordersHypothalamic-pituitary-adrenal axisT cellsSuicidal ideationHPA axisPsychological disordersSympathetic nervous systemPsychiatric diseasesBlood-brain barrierDisordersMechanisms of T cellsChronic inflammatory skin conditionSkin diseasesEfficacy of treatmentPathogenesis of psoriasisInflammatory skin conditionProgression of psoriasisSecrete cytokinesIdeationPsoriasisComorbiditiesAnxietyDepressionNervous system
2023
Self‐Assembled nanoparticles of natural bioactive molecules enhance the delivery and efficacy of paclitaxel in glioblastoma
Li Y, Zhao Q, Zhu X, Zhou L, Song P, Liu B, Tian D, Chen Q, Zhou J, Deng G. Self‐Assembled nanoparticles of natural bioactive molecules enhance the delivery and efficacy of paclitaxel in glioblastoma. CNS Neuroscience & Therapeutics 2023, 30: e14528. PMID: 38044793, PMCID: PMC11017454, DOI: 10.1111/cns.14528.Peer-Reviewed Original ResearchBlood-brain barrierP-gp inhibitorsCerebral vascular endothelial cellsStrong anti-tumor effectsCommon primary malignant tumorApplication of paclitaxelEfflux transportersPrimary malignant tumorsUse of paclitaxelEfficacy of paclitaxelAnti-tumor effectsPeripheral solid tumorsCentral nervous systemNatural bioactive moleculesEffective anti-cancer drugsP-gp transporterVascular endothelial cellsBlood concentrationsMalignant tumorsGlioma treatmentNervous systemP-gpAnti-cancer drugsSolid tumorsTumor tissuePericytes are protective in experimental pneumococcal meningitis through regulating leukocyte infiltration and blood–brain barrier function
Teske N, Dyckhoff-Shen S, Beckenbauer P, Bewersdorf J, Engelen-Lee J, Hammerschmidt S, Kälin R, Pfister H, Brouwer M, Klein M, Glass R, van de Beek D, Koedel U. Pericytes are protective in experimental pneumococcal meningitis through regulating leukocyte infiltration and blood–brain barrier function. Journal Of Neuroinflammation 2023, 20: 267. PMID: 37978545, PMCID: PMC10655320, DOI: 10.1186/s12974-023-02938-z.Peer-Reviewed Original ResearchConceptsModel of pneumococcal meningitisPneumococcal meningitisLeukocyte infiltrationAnimal model of pneumococcal meningitisPrevented blood-brain barrierToll-like receptor inhibitorsDegree of leukocyte infiltrationSerotypes of Streptococcus pneumoniaeUnfavorable disease courseBlood-brain barrier disruptionHuman pericytesExperimental pneumococcal meningitisBlood-brain barrier integrityRegulating leukocyte infiltrationBlood-brain barrier functionRegulation of cerebral blood flowAdult mouse modelInfection in vivoUpregulation of chemokine expressionIncreased cerebral edemaMaintenance of blood-brain barrier integrityBlood-brain barrierCerebral blood flowMouse meningitis modelIn vitro studiesAdvantages and Disadvantages of Nutraceuticals
Rajalakshmi R, Melians M, Pon F, Cosio D, Buvarahamurthy V, Jayakumar A, Paidas M. Advantages and Disadvantages of Nutraceuticals. Nutritional Neurosciences 2023, 245-286. DOI: 10.1007/978-981-99-0677-2_15.Peer-Reviewed Original ResearchEfficacy of nutraceuticalsHeavy metalsLimitations of nutraceuticalsPoor bioavailabilityDrug bioavailabilityBioavailabilityNutraceutical marketLack of experimental evidencePrevent chronic diseasesContaminationPatient health issuesSide effectsHealth professionalsNutrientsNutraceuticalsSide effect profileMetalChronic diseasesRaw materialsHealth issuesToxicityToxic side effectsCompoundsDrug-drug interactionsBlood-brain barrierTakeaim Lymphoma: An Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies
Grommes C, Tun H, Rosenthal A, Lunning M, Ramchandren R, Regales L, Zhao W, Lane M, Wang C, von Roemeling R, Isufi I, Leslie L, Nowakowski G. Takeaim Lymphoma: An Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies. Blood 2023, 142: 4497. DOI: 10.1182/blood-2023-189746.Peer-Reviewed Original ResearchInterleukin-1 receptor-associated kinase 4Non-Hodgkin lymphomaFMS-like tyrosine kinase 3Bid dose levelToll-like receptorsDose escalationBTK inhibitorsNHL patientsDose levelsAcceptable long-term safety profileRefractory non-Hodgkin lymphomaLong-term safety profileB-cell non-Hodgkin lymphomaBruton tyrosine kinase inhibitorsBTK inhibitor resistanceContinuous oral dosingMurine PDX modelPhase 2 doseRelapsed/Refractory Non-Hodgkin LymphomaMedian treatment durationOpen-label trialRefractory hematologic malignanciesBlood-brain barrierPreliminary efficacy dataNovel oral inhibitor
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply